RESMED INC 4

Chairman and CEO Michael J. Farrell exercised 4,991 ResMed stock options at $146.34 and sold the resulting 4,991 shares at an average $218.55, leaving 466,223 shares held directly (plus 2,090 indirectly).

On July 7, 2026, ResMed Inc. Chairman and CEO Michael J. Farrell exercised 4,991 stock options for ResMed common stock at an exercise price of $146.34 per share and immediately sold the same 4,991 shares in the open market at a weighted average price of $218.5475 per share pursuant to a Rule 10b5-1 trading plan adopted on October 31, 2024. The option exercise generated shares that increased his direct holdings before the sale to 471,214 shares, after which the sale reduced his direct ownership to 466,223 shares, plus 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust. The option award relates to a grant first exercisable on November 11, 2020 with vesting at one-third per year and had an exercise price of $146.34 per share; the Form 4 indicates total derivative holdings (including this option) of 19,966 options after the transaction. Based on the reported prices, the sale proceeds were approximately $1.09 million and the underlying option exercise cost was approximately $0.73 million, and using the current share price, Farrell’s remaining direct equity stake is worth roughly $96 million, with a modest additional amount held indirectly via the family trust.

Filing Facts

CIK

943819

Ticker

RMD

Form

4

Source Type

sec

Accession

0000943819-26-000038

Alert Tier

6